18F-FTC-146 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 206 | Fragile X syndrome | 1 |
206. Fragile X syndrome
Clinical trials : 104 / Drugs : 87 - (DrugBank : 32) / Drug target genes : 54 - Drug target pathways : 79
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04314856 (ClinicalTrials.gov) | January 12, 2021 | 11/3/2020 | Novel Clinical Target in Fragile X Syndrome | Sigma-1 Receptors: A Novel Clinical Target in Fragile X Syndrome | Fragile X Syndrome (FXS) | Drug: 18F-FTC-146 | Guido A. Davidzon, MD, MS | NULL | Recruiting | 18 Years | 65 Years | All | 20 | Phase 1 | United States |